Logo for Galapagos NV

Galapagos Investor Relations Material

Latest events

Logo for Galapagos NV

Investor Update

Galapagos
Logo for Galapagos

Investor Update

8 Jan, 2025
Logo for Galapagos

Q3 2024

31 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Galapagos NV

Access all reports
Segment Data
Access more data
Net revenue by
Source
Collaboration revenues
Product net sales
Expenses by
Financials
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises four Phase 2 programs, three Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.